Minerva Surgical has launched AUBandMe.com at the 50th Global Congress of the American Association of Gynecologic Laparoscopists, focusing on Abnormal Uterine Bleeding (AUB) treatment education. AUB affects 1 in 3 women, often leading to untreated conditions and significant quality of life deterioration. The initiative aims to empower women with knowledge about available non-hormonal treatments and improve their treatment options. CEO Dave Clapper emphasized the need for better awareness and solutions for women suffering from heavy periods.
Minerva Surgical has successfully closed its initial public offering, selling 6,250,000 shares at $12.00 each, raising approximately $75.0 million. The offering was managed by J.P. Morgan, Piper Sandler, UBS, and SVB Leerink. The proceeds will support the company's development of minimally invasive solutions for Abnormal Uterine Bleeding (AUB), targeting a market need for alternatives to hysterectomy. The registration statement for this offering was effective as of October 21, 2021. This press release serves as a notice and does not constitute an offer or solicitation.
Minerva Surgical, a company specializing in women's healthcare, has priced its initial public offering (IPO) at $12.00 per share, totaling $75.0 million for 6,250,000 shares. Trading on the Nasdaq under the symbol UTRS is set to commence on October 22, 2021, with the offering expected to close on October 26, 2021. The underwriters have a 30-day option to purchase an additional 937,500 shares. This IPO aims to fund the continued development of minimally invasive solutions for abnormal uterine bleeding, a significant concern for women's health.